Nemolizumab

Nemolizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target IL31RA
Clinical data
Synonyms CIM-331
Routes of
administration		 Subcutaneous injection
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Metabolism Proteolytic enzymes
Identifiers
CAS Number
ChemSpider
  • none
UNII

Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis.[1] It is a monoclonal antibody that blocks the interleukin-31 receptor A.[2] Results of a Phase II clinical trial were published in March 2017.[3]

Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[4]

References

  1. ↑ H. Spreitzer (27 March 2017). "Neue Wirkstoffe - Nemolizumab". Österreichische Apothekerzeitung (in German) (7/2017).
  2. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74" (PDF). WHO Drug Information. World Health Organisation. 29 (3): 411. 2015.
  3. ↑ Ruzicka, T; Hanifin, J. M.; Furue, M; Pulka, G; Mlynarczyk, I; Wollenberg, A; Galus, R; Etoh, T; Mihara, R; Yoshida, H; Stewart, J; Kabashima, K (2017). "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis". New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150.
  4. ↑ "Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.